awmsg logo



paclitaxel albumin-bound nanoparticles (Abraxane®)


Reference No. 1666

Publication date:
30/06/2015


Appraisal information

paclitaxel albumin-bound nanoparticles (Abraxane®) 5 mg/ml powder for solution for infusion


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/06/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, paclitaxel albumin-bound nanoparticles (Abraxane®) cannot be endorsed for use within NHS Wales in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.